Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Cabaletta Bio, Inc.
Cabaletta Bio is a clinical-stage biotech company developing engineered T cell therapies to treat autoimmune diseases.
Cabaletta Bio is a biotech company trying to bring a powerful idea from cancer medicine into the world of autoimmune disease. Its treatments are made from a patient's own immune cells, which are taken out, engineered in a lab, and then put back into the body. The goal is to reset a malfunctioning immune system rather than simply suppress it with drugs that must be taken forever.
The core technology is called CABA-201, and it is a one-time infusion built from the patient's own T cells. The cells are engineered to carry a receptor that seeks out and removes the specific B cells that produce harmful antibodies. Those B cells are the troublemakers behind many autoimmune conditions, where the body's defenses mistakenly attack its own tissue. Wiping out those cells gives the immune system a chance to reboot from a cleaner starting point. Cabaletta is testing this approach in a range of diseases, including myositis, lupus, and systemic sclerosis. Because the therapy is made from the patient's own cells, each dose is a custom, living drug, which makes the science promising but the manufacturing and logistics complicated. The company does not yet sell anything or earn meaningful revenue from products; like most clinical-stage biotechs, it spends heavily on research and trials and funds itself through investors and capital raises.
The big question the company must answer is whether its treatment works safely and well enough in trials to win approval. If it does, the payoff could be far simpler and more durable treatment for people stuck on lifelong immune-suppressing drugs. Until then, Cabaletta is a research story, and its value rises and falls with clinical trial data. It is headquartered in Philadelphia.
Saved answer · last researched 15 Nov 2026